-
Translational Notes: Building bridges Table 1. Trajectories of recipients of the California Institute for Quantitative Biosciences' (QB3) Bridging-the-Gap Awards. Principal investigator QB3 campus Award year …
Published on 5/3/2012
-
Johnson & Johnson has joined the ranks of funders supporting the California Institute for Quantitative Biosciences Bridging-the-Gap Awards by providing two grants for research on an implantable pancreas for type 1 …
Published on 5/3/2012
-
Texas translation Table 1. Cancer Prevention & Research Institute of Texas' latest grant recipients. Recipient Program Funding ($M) Companies Asuragen Inc. Mutational profiling of tumors by next-generation DNA …
Published on 4/26/2012
-
The taxpayer-backed Cancer Prevention & Research Institute of Texas is moving downstream from its initial focus on basic research in oncology. This month, the institute announced its latest round of grants--this time …
Published on 4/26/2012
-
Building tools against autism Table 1. Participants in the European Autism Interventions-A Multicentre Study for Developing New Medications (EU-AIMS) consortium. Academic centers and research organizations …
Published on 4/19/2012
-
An academic-industry consortium headed by King's College London and Roche launched this month with €29.6 million ($38.9 million) to develop research tools and diagnostics for autism spectrum disorder and to help select …
Published on 4/19/2012
-
Phenotypic screening for drug discovery is making a comeback, but not everybody is embracing it. Some pharmas, such as Novartis and GSK, are placing a bet on phenotypic screening, whereas others, such as Genentech, are …
Published on 4/12/2012
-
Merck is investing up to $90 million over the next seven years to fund the California Institute for Biomedical Research. The pharma is hoping the wide spectrum of translational research to be covered by the institute …
Published on 3/22/2012
-
Whereas most academic institutes tackle the translational gap by pushing their assets further along in hopes of attracting an industry partner, University Hospitals is taking the opposite approach by forming a company …
Published on 3/15/2012
-
Three Florida-based institutions are pooling resources in the Personalized Medicine Partnership of Florida to accelerate the discovery of markers that could predict individual responses to cancer, metabolic and …
Published on 3/1/2012
-
Seeing the (En)light Table 1. Enlight's offspring. Company Technology Founded Endra Inc. Photoacoustic molecular imaging 2008 Entrega Inc. Formulation technology for oral delivery of peptides and proteins …
Published on 1/19/2012
-
The Scripps Research Institute has decided that the kinds of broad deals it used to do with industry do not work anymore. Instead, the institute now hopes to forge a series of smaller, more focused collaborations with …
Published on 1/19/2012
-
AstraZeneca and Novo Nordisk have come off the sidelines to partner with Enlight Biosciences, making them the sixth and seventh pharmas currently working with Enlight to form platform companies.
Published on 1/19/2012
-
A conversation with Laurie Glimcher Table 1. Putting a spin (out) on New York City medical centers. Companies focusing on therapeutics, diagnostics or medical devices that were founded from 2009-2011 based on …
Published on 1/12/2012
-
As Laurie Glimcher was preparing to take over as dean of Weill Cornell, SciBX caught up with her to discuss research priorities for academic medical centers, the most effective models for promoting industry–academic …
Published on 1/12/2012
-
The U.K.'s Medical Research Council has partnered with AstraZeneca to make the pharma's shelved compounds available to academics investigating basic disease mechanisms. A first call for proposals is in progress.
Published on 1/5/2012
-
With 14 projects in place, the NIH's Therapeutics for Rare and Neglected Diseases program will shift its focus from finding projects to building infrastructure and advancing programs into the clinic.
Published on 12/15/2011
-
Translational Notes: TRND take two Table 1. TRND partnerships. List of NIH Therapeutics for Rare and Neglected Diseases (TRND) partnerships as of Dec. 12, 2011. Source: NIH Center for Translational Therapeutics …
Published on 12/15/2011
-
Cancer Research UK is brokering partnerships between its stable of academics and companies looking for a stake in early cancer discoveries. AstraZeneca is the charity's anchor collaborator with three projects, including…
Published on 11/17/2011
-
Alvos and Ablaris are using peptide-receptor pairs identified by MD Anderson researchers to target therapeutic payloads in cancer and obesity. The center now has provided preclinical proof-of-concept data and …
Published on 11/17/2011
-
Hands-off incubator Box 1. Incubators no more. In 2007, Pfizer Inc. and Biogen Idec Inc. created incubators that provided both space and funding for startups. The Biogen Idec Innovation Incubator funded and housed …
Published on 11/3/2011
-
Johnson & Johnson is opening a life sciences incubator in San Diego that provides no funding and receives no IP rights from its occupants, unlike now-defunct facilities started by companies such as Biogen Idec and …
Published on 11/3/2011
-
The pharma-led Quebec Consortium for Drug Discovery is providing C$1.2 million in funding for a quartet of projects that it hopes will apply unconventional, out-of-the-box thinking and lead to breakthrough research …
Published on 10/20/2011
-
Eli Lilly is rolling out its Open Innovation Drug Discovery platform to cast a wide net for finding innovative molecules from external investigators in the company's core disease focus areas. The pharma has also joined …
Published on 10/13/2011
-
After two years of funding pilot partnerships, the NIH's Therapeutics for Rare & Neglected Diseases program has announced its first round of competitively awarded projects. The awards to three biotechs and an academic …
Published on 10/13/2011